Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
TT-4 in Malignant Pleural Mesothelioma: NCT04969315 Clinical Landscape Report 2026
28 September 2026
NCT04969315 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitomycin in Malignant Mesothelioma of Peritoneum: NCT05001880 Clinical Landscape Report 2026
28 September 2026
NCT05001880 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Ipilimumab in Malignant Mesothelioma of Peritoneum: NCT05041062 Clinical Landscape Report 2026
28 September 2026
NCT05041062 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Bintrafusp alfa in Malignant Pleural Mesothelioma: NCT05005429 Clinical Landscape Report 2026
28 September 2026
NCT05005429 clinical landscape for Malignant Pleural Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
KZR-261 in Uveal Melanoma: NCT05047536 Clinical Landscape Report 2026
28 September 2026
NCT05047536 clinical landscape for Uveal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Metoprolol Succinate in Cardiomyopathies: NCT05066633 Clinical Landscape Report 2026
28 September 2026
NCT05066633 clinical landscape for Cardiomyopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Unresectable Pleural Malignant Mesothelioma: NCT05071014 Clinical Landscape Report 2026
28 September 2026
NCT05071014 clinical landscape for Unresectable Pleural Malignant Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Tocilizumab in Pancreatic adenocarcinoma: NCT05070247 Clinical Landscape Report 2026
28 September 2026
NCT05070247 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Brogidirsen in Muscular Dystrophy, Duchenne: NCT05135663 Clinical Landscape Report 2026
28 September 2026
NCT05135663 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Delandistrogene moxeparvovec in Muscular Dystrophy, Duchenne: NCT05096221 Clinical Landscape Report 2026
28 September 2026
NCT05096221 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Deramiocel in Muscular Dystrophy, Duchenne: NCT05126758 Clinical Landscape Report 2026
28 September 2026
NCT05126758 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Vamorolone in Muscular Dystrophy, Duchenne: NCT05185622 Clinical Landscape Report 2026
28 September 2026
NCT05185622 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.